tiprankstipranks
Trending News
More News >
Artiva Biotherapeutics: Strategic Delay and Expanded Research Justify Buy Rating
PremiumRatingsArtiva Biotherapeutics: Strategic Delay and Expanded Research Justify Buy Rating
2M ago
Artiva Biotherapeutics, Inc.: Strategic Advancements and Market Potential in Biotherapeutics Highlighted by Phase IIa Trial Initiation and FDA Clearance
Premium
Ratings
Artiva Biotherapeutics, Inc.: Strategic Advancements and Market Potential in Biotherapeutics Highlighted by Phase IIa Trial Initiation and FDA Clearance
2M ago
Artiva Biotherapeutics reports Q1 EPS (83c) vs. ($17.24) last year
Premium
The Fly
Artiva Biotherapeutics reports Q1 EPS (83c) vs. ($17.24) last year
2M ago
Artiva Biotherapeutics Reports 2024 Financial Results
PremiumCompany AnnouncementsArtiva Biotherapeutics Reports 2024 Financial Results
3M ago
Artiva Biotherapeutics: Strong Buy Rating Backed by Promising Pipeline and Financial Stability
Premium
Ratings
Artiva Biotherapeutics: Strong Buy Rating Backed by Promising Pipeline and Financial Stability
3M ago
Artiva Biotherapeutics price target lowered to $20 from $23 at Cantor Fitzgerald
Premium
The Fly
Artiva Biotherapeutics price target lowered to $20 from $23 at Cantor Fitzgerald
3M ago
Artiva Biotherapeutics Reports Q3 2024 Financial Results
PremiumCompany AnnouncementsArtiva Biotherapeutics Reports Q3 2024 Financial Results
8M ago
Artiva Biotherapeutics reports Q3 EPS (92c), consensus (91c)
Premium
The Fly
Artiva Biotherapeutics reports Q3 EPS (92c), consensus (91c)
8M ago
Artiva Biotherapeutics appoints Alison Moore, Ph.D., to Its Board of Directors
Premium
The Fly
Artiva Biotherapeutics appoints Alison Moore, Ph.D., to Its Board of Directors
9M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100